Nexstim logo

Nexstim to present at Nordic Life Science Days Conference in Stockholm

07 September 2015

Nexstim Plc (NXTMH:HEX, NXTMS:STO), a medical technology company aiming to improve rehabilitation for stroke patients through the use of non-invasive brain stimulation, announces today that Chief Financial Officer, Mikko Karvinen, will be presenting at the Nordic Life Science Days conference in Stockholm on Thursday 10 September 2015.

The event is largest Nordic partnering conference for the global Life Science industry, attracting leading decision makers from the Life Science sector, not only from biotech, pharma and medtech but also from finances, research, policy and regulatory authorities. For information about the conference, please visit The Company’s presentation will be made available at following the conference.

For further information please visit or contact:

Janne Huhtala, Chief Executive Officer
+358 (0)40 8615046                                                                                                                                                                                                                                                         

UB Capital Oy (Certified Adviser)  
+358 (0)9 2538 0225                                                                                                                

Consilium Strategic Communications    
Mary-Jane Elliott / Ivar Milligan / Laura Thornton     
+44 (0)20 3709 5700                                                                                                                                             

About Nexstim Plc
Nexstim is a medical technology company aiming to improve rehabilitation for stroke patients. Nexstim has pioneered its technology in brain diagnostics with the Navigated Brain Stimulation (NBS) system as the first and only FDA-cleared and CE-marked navigated Transcranial Magnetic Stimulation (nTMS) device for pre-surgical mapping of the motor and speech cortices. Based on the same technology platform, the company has developed a device for stroke therapy called Navigated Brain Therapy (NBT®). In H1 2014, Nexstim initiated a two-year pivotal Phase III study at 12 sites in the US aiming to demonstrate the effectiveness of NBT® and gain FDA clearance for commercialisation in post-acute stroke therapy in the US. Nexstim's shares are listed on Nasdaq First North Finland and Nasdaq First North Sweden. For more information please visit


Back to Press Releases